0241: A Randomised Phase II Trial in Advanced Epithelial Ovarian Cancer (Eoc), with Prospective Translational End-Points to Predict Chemotherapy Response (Ctcr-Ov01)
- Abstract:
- Aim The aim of this study was to find out whether pretreatment cytokine/cytokine receptor levels influence prognosis. The levels of TNFalfa, IL-1beta, IL-6, sIL-6R, IL-8, IL-10, sIL-2R, sIL-6R, sTNF RII, G-CSF, M-CSF, GM-CSF, bFGF and VEGF were investigated in the sera of untreated ovarian cancer patients. Methods The sera of 71 untreated patients with ovarian cancer were assessed. All tumors were verified histologically. The tumors were staged according to FIGO. All patients were nonseptic and with no symptoms of infection. Sera of 50 healthy volunteers served as controls. Serum samples were stored at -70 °C before assay. Concentrations of serum cytokines were determined by the ELISA of R&D Systems Inc., Minneapolis, MN. In addition, all the patients’ sera were assayed for CA 125 levels with Abbott kits. The assays were performed as described by the manufacturers. For overall survival analysis, the Kaplan-Meier method, log-rank test and multivariate analysis with Cox’s proportional hazard model were used. Results The analysis revealed that circulating VEGF, bFGF, sTNF RII and M-CSF were associated with survival, but only VEGF (p , 0.05) and sTNF RII (p , 0.02) were found to independently influence prognosis in ovarian cancer patients. Conclusions The results suggest that some cytokines and their soluble receptors, known to play an important role in cancer development and progression, might be of clinical importance for the diagnosis and prognosis in ovarian cancer, especially VEGF and sTNF RII that proved to have a value of independent prognostic factors.
- Authors:
- AA Ahmed, A-L Vallier, C Parkinson, M Iddawela, J Lat-Imer, R Crawford, JD Brenton, HM Earl
- Journal:
- International Journal of Gynecological Cancer
- Citation info:
- 16:668
- Publication date:
- 1st Oct 2006
- Full text
- DOI